Rigel Pharmaceuticals, Inc. (RIGL) EPS Estimated At $-0.16

July 13, 2018 - By Nellie Frank

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) LogoInvestors sentiment decreased to 1.23 in Q1 2018. Its down 0.83, from 2.06 in 2017Q4. It is negative, as 13 investors sold Rigel Pharmaceuticals, Inc. shares while 27 reduced holdings. 14 funds opened positions while 35 raised stakes. 126.59 million shares or 0.43% less from 127.13 million shares in 2017Q4 were reported.
Renaissance Technology accumulated 689,926 shares. New York-based Hudson Bay Cap Lp has invested 0.09% in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL). Cubist Systematic Strategies Ltd accumulated 20,193 shares. Nea Communication Ltd Liability Corporation reported 3.24M shares. Citadel Advsrs accumulated 3.15M shares. Art Advsrs Limited Liability Com has 0.01% invested in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL). Price T Rowe Assoc Md has invested 0% in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL). Balyasny Asset Mngmt Ltd Liability reported 67,550 shares. Morgan Stanley owns 701,435 shares. New York-based J Goldman L P has invested 0.13% in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL). Mackenzie Financial Corp owns 0% invested in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) for 77,181 shares. California State Teachers Retirement holds 224,715 shares. 300 are owned by San Francisco Sentry Investment (Ca). Fort Point Cap Ltd Limited Liability Company stated it has 0.02% of its portfolio in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL). Ubs Asset Mgmt Americas holds 65,483 shares or 0% of its portfolio.

Since April 20, 2018, it had 0 insider buys, and 2 insider sales for $34,482 activity.

Analysts expect Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) to report $-0.16 EPS on August, 7.They anticipate $0.00 EPS change or 0.00 % from last quarter’s $-0.16 EPS. After having $-0.17 EPS previously, Rigel Pharmaceuticals, Inc.’s analysts see -5.88 % EPS growth. The stock decreased 1.37% or $0.04 during the last trading session, reaching $2.87. About 1.60M shares traded. Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) has risen 61.57% since July 13, 2017 and is uptrending. It has outperformed by 49.00% the S&P500.

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Ratings Coverage

Among 5 analysts covering Rigel (NASDAQ:RIGL), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Rigel had 14 analyst reports since January 19, 2018 according to SRatingsIntel. The stock has “Buy” rating by H.C. Wainwright on Wednesday, March 7. The rating was maintained by BMO Capital Markets on Wednesday, April 18 with “Outperform”. The firm has “Buy” rating given on Tuesday, April 17 by Cantor Fitzgerald. The firm has “Buy” rating by H.C. Wainwright given on Tuesday, April 3. H.C. Wainwright maintained the shares of RIGL in report on Friday, February 2 with “Buy” rating. H.C. Wainwright maintained the stock with “Buy” rating in Wednesday, May 2 report. The company was maintained on Wednesday, April 4 by Jefferies. The company was maintained on Tuesday, March 6 by Cantor Fitzgerald. The firm earned “Buy” rating on Wednesday, April 18 by H.C. Wainwright. As per Wednesday, May 2, the company rating was maintained by BMO Capital Markets.

Rigel Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the discovery and development of drugs in the therapeutic areas of immunology, oncology, and immuno-oncology. The company has market cap of $469.48 million. The company's clinical programs include fostamatinib, an oral spleen tyrosine kinase inhibitor, which has completed Phase III clinical program for immune thrombocytopenia purpura; and Phase II clinical study for autoimmune hemolytic anemia and IgA nephropathy. It currently has negative earnings. It is also developing two oncology product candidates, which are in Phase I and Phase II.

Another recent and important Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) news was published by Investorplace.com which published an article titled: “10 Strong Buy Stocks for Under $10” on July 12, 2018.

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.